ESR1 and breast carcinoma: TNBC has traditionally been treated as a homogenous group with no available targeted therapies and a reliance on sequential standard chemotherapies, resulting in poor outcomes relative to oestrogen receptor (ER)-positive or HER2-positive breast cancers.